LIAISON® XL MUREX Anti-HBs, LIAISON® XL MUREX Control Anti-HBs and LIAISON® XL MUREX Anti-HBs Verifiers

FDA Premarket Approval P180039

Pre-market Approval Supplement Details

The liaison xl murex anti-hbs is an in vitro chemiluminescent immunoassay (clia) for the qualitative and quantitative determination of antibody to hepatitis b surface antigen (anti-hbs) in human adult and pediatric (2 – 21 years) serum and plasma (lithium and sodium heparin and k2 edta) including separator tubes, on the liaison xl analyzer. Assay results in conjunction with other hepatitis b virus (hbv) serological markers and clinical information may be used as an aid in the diagnosis of hbv infection in patients with symptoms of hepatitis or who may be at risk for hbv infection. The assay results may be used as an aid in the determination of susceptibility to hbv infection in individuals prior to or following hbv vaccination or where vaccination status is unknown. The assay is not approved for use in screening blood, plasma or tissue donors. The liaison xl murex control anti-hbs (negative and positive) is intended for use as assayed quality control samples to monitor the performance of the liaison xl murex anti-hbs assay. The performance characteristics of liaison xl murex control anti-hbs have not been established for any other assays or instrument platforms. The liaison xl murex anti-hbs verifiers (level 1, 2, 3, and level 4) are assayed quality control materials intended for the quantitative verification of calibration and reportable range of the liaison xl murex anti-hbs assay. The performance characteristics of liaison xl murex anti-hbs verifiers have not been established in connection with any other assay or instrument platforms.

DeviceLIAISON® XL MUREX Anti-HBs, LIAISON® XL MUREX Control Anti-HBs and LIAISON® XL MUREX Anti-HBs Verifiers
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantDiaSorin Inc.
Date Received2018-09-26
Decision Date2020-02-21
PMAP180039
SupplementS
Product CodeLOM 
Advisory CommitteeMicrobiology
Expedited ReviewNo
Combination Product No
Applicant Address DiaSorin Inc. 1951 Northwestern Avenue stillwater, MN 55082

Supplemental Filings

Supplement NumberDateSupplement Type
P180039Original Filing
S013 2022-11-10 30-day Notice
S012
S011 2022-04-05 Real-time Process
S010 2022-04-05 30-day Notice
S009 2022-02-04 Real-time Process
S008 2021-11-23 30-day Notice
S007 2021-11-23 30-day Notice
S006 2021-11-23 30-day Notice
S005
S004 2021-05-27 Real-time Process
S003
S002 2020-07-16 30-day Notice
S001 2020-06-18 Real-time Process

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.